Format

Send to

Choose Destination
See comment in PubMed Commons below
Biochemistry. 2011 Dec 6;50(48):10419-21. doi: 10.1021/bi201490t. Epub 2011 Nov 7.

Retargeted clostridial neurotoxins as novel agents for treating chronic diseases.

Author information

1
Department of Neuroscience, Howard Hughes Medical Institute, University of Wisconsin, Madison, Wisconsin 53706-1510, United States.

Abstract

Botulinum neurotoxin (BoNT) A and B are used to treat neuropathic disorders; if retargeted, these agents could be used to treat medical conditions that involve secretion from nonneuronal cells. Here, we report novel strategies for successfully retargeting BoNTs, and also tetanus neurotoxin (TeNT), to primary human blood monocyte-derived macrophages where BoNT/B inhibited the release of tumor necrosis factor-α, a cytokine that plays a key role in inflammation. Furthermore, mice treated with retargeted BoNT/B exhibited a significant reduction in macrophage (MΦ) recruitment, indicating that these toxins can be used to treat chronic inflammation.

PMID:
22047069
PMCID:
PMC3226321
DOI:
10.1021/bi201490t
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Chemical Society Icon for PubMed Central
    Loading ...
    Support Center